1 |
Nolen B, Velikokhatnaya L, Marrangoni A, et al (2010). Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol, 117, 440-5.
DOI
ScienceOn
|
2 |
Yavuzcan A, Caglar M, Ozgu E, et al (2013). Should cutoff values of the risk of malignancy index be changed for evaluation of adnexal masses in Asian and Pacific populations?. Asian Pac J Cancer Prev, 13, 5455-9.
|
3 |
Lin J-Y, Qin J-B, Li X-Y, Dong P, Yin B-D (2012). Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and metaanalysis. Asian Pac J Cancer Prev, 13, 5427-32.
과학기술학회마을
DOI
ScienceOn
|
4 |
Mokhtar N, Thevarajah M, Ma N, M I (2012). Human epididymis protein 4 reference intervals in a multiethnic Asian women population. Asian Pac J Cancer Prev, 13, 6391-5.
과학기술학회마을
DOI
ScienceOn
|
5 |
Moore RG, Brown AK, Miller MC, et al (2008). The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 108, 402-8.
DOI
ScienceOn
|
6 |
Moore RG, McMeekin DS, Brown AK, et al (2009). A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol, 112, 40-6.
DOI
ScienceOn
|
7 |
Rosen DG, Wang L, Atkinson JN, et al (2005). Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol, 99, 267-77.
DOI
ScienceOn
|
8 |
Van Gorp T, Cadron I, Despierre E, et al (2011). HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 104, 863-70.
DOI
ScienceOn
|
9 |
Wahidin M, Noviani R, Hermawan S, et al (2012). Populationbased cancer registration in Indonesia. Asian Pac J Cancer Prev, 13, 1709-10.
DOI
ScienceOn
|
10 |
Chang X, Ye X, Dong L, et al (2011). Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer. 21, 852-8.
DOI
ScienceOn
|
11 |
Aziz MF (2009). Gynecological cancer in Indonesia. J Gynecol Oncol. 20, 8-10.
DOI
ScienceOn
|
12 |
Havrilesky LJ, Whitehead CM, Rubatt JM, et al (2008). Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 110, 374-82.
DOI
ScienceOn
|
13 |
Bian J, Li B, Kou X-J, Liu T-Z, Ming L (2013). Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer. Asian Pac J Cancer Prev, 13, 6241-43.
과학기술학회마을
DOI
ScienceOn
|
14 |
Boyle P, Levin B (2008). World Cancer Report. In: WHO, editor. Switzerland: International Agency for Research on Cancer.
|
15 |
Chan KK, Chen CA, Nam JH, et al (2013). The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecol Oncol, 128, 239-44.
DOI
ScienceOn
|
16 |
Hennessy BT, Coleman RL, Markman M(2009). Ovarian cancer. Lancet. 374, 1371-82.
DOI
ScienceOn
|
17 |
Holcomb K, Vucetic Z, Miller MC, Knapp RC (2011). Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol. 205, 1-6.
DOI
ScienceOn
|
18 |
Huhtinen K, Suvitie P, Hiissa J, et al (2009). Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer, 100, 1315-9.
DOI
ScienceOn
|
19 |
Pauler DK, Menon U, McIntosh M, et al (2001). Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev. 10, 489-93.
|